Table 1

Reticulocyte CHCM (g/L) determined on fresh blood, after swelling and subsequent volume reduction (VR) in sickle and normal cells

Fresh reticulocytes, before nystatin treatmentSwollen reticulocytes, after nystatin treatmentAfter VR in HBS 7.4, no ureaAfter VR in HBS 7.4 plus 600 mM ureaP, paired t test, no urea vs urea
SS 335 (10)* 250 (20) 315 (07) 38.9 (21) < .001 
AA 308 (17) 244 (18)§ 275 (08)§ 33.8 (22)§ < .001 
P, unpaired t test, SS vs AA < .01 NS < .001 < .001  
Fresh reticulocytes, before nystatin treatmentSwollen reticulocytes, after nystatin treatmentAfter VR in HBS 7.4, no ureaAfter VR in HBS 7.4 plus 600 mM ureaP, paired t test, no urea vs urea
SS 335 (10)* 250 (20) 315 (07) 38.9 (21) < .001 
AA 308 (17) 244 (18)§ 275 (08)§ 33.8 (22)§ < .001 
P, unpaired t test, SS vs AA < .01 NS < .001 < .001  

Reticulocyte CHCM was measured in fresh blood within 4 hours of drawing into EDTA tubes. After washing in isotonic HBS, cells were treated with nystatin, washed as described in “Materials and methods,” under “Nystatin treatment,” and resuspended at 0.20 hematocrit in HBS 7.4. Samples were reserved on ice for measurement of initial CHCM (swollen reticulocytes) and then diluted to 0.02 hematocrit in 37°C buffer, either HBS 7.4 (control) or HBS 7.4 plus 600 mM urea. After 2 hours of incubation, samples were transferred to cold HBS 7.4, washed, and resuspended for Advia 120 analysis. Data shown are mean, with SEM shown in parentheses.

*

n = 6.

n = 12.

n = 7.

§

n = 13.

Close Modal

or Create an Account

Close Modal
Close Modal